These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 37051929

  • 1. Contribution of APOE Genetic Variants to Dyslipidemia.
    Bea AM, Larrea-Sebal A, Marco-Benedi V, Uribe KB, Galicia-Garcia U, Lamiquiz-Moneo I, Laclaustra M, Moreno-Franco B, Fernandez-Corredoira P, Olmos S, Civeira F, Martin C, Cenarro A.
    Arterioscler Thromb Vasc Biol; 2023 Jun; 43(6):1066-1077. PubMed ID: 37051929
    [Abstract] [Full Text] [Related]

  • 2. Apolipoprotein E2-Dunedin (228 Arg replaced by Cys): an apolipoprotein E2 variant with normal receptor-binding activity.
    Wardell MR, Rall SC, Brennan SO, Nye ER, George PM, Janus ED, Weisgraber KH.
    J Lipid Res; 1990 Mar; 31(3):535-43. PubMed ID: 2341812
    [Abstract] [Full Text] [Related]

  • 3. Diagnosis of Familial Dysbetalipoproteinemia Based on the Lipid Abnormalities Driven by APOE2/E2 Genotype.
    Bea AM, Cenarro A, Marco-Bened V, Laclaustra M, Martn C, Ibarretxe D, Pint X, Arrobas T, Vials C, Civeira F, Olmos S.
    Clin Chem; 2023 Feb 01; 69(2):140-148. PubMed ID: 36644927
    [Abstract] [Full Text] [Related]

  • 4. Apolipoprotein E2 (Arg136 --> Cys) mutation in the receptor binding domain of apoE is not associated with dominant type III hyperlipoproteinemia.
    März W, Hoffmann MM, Scharnagl H, Fisher E, Chen M, Nauck M, Feussner G, Wieland H.
    J Lipid Res; 1998 Mar 01; 39(3):658-69. PubMed ID: 9548597
    [Abstract] [Full Text] [Related]

  • 5. Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype.
    Kypreos KE, Li X, van Dijk KW, Havekes LM, Zannis VI.
    Biochemistry; 2003 Aug 26; 42(33):9841-53. PubMed ID: 12924933
    [Abstract] [Full Text] [Related]

  • 6. Hyperlipidemia of ApoE2(Arg(158)-Cys) and ApoE3-Leiden transgenic mice is modulated predominantly by LDL receptor expression.
    van Dijk KW, van Vlijmen BJ, de Winther MP, van 't Hof B, van der Zee A, van der Boom H, Havekes LM, Hofker MH.
    Arterioscler Thromb Vasc Biol; 1999 Dec 26; 19(12):2945-51. PubMed ID: 10591674
    [Abstract] [Full Text] [Related]

  • 7. Reversal of hypercholesterolemia in apolipoprotein E2 and apolipoprotein E3-Leiden transgenic mice by adenovirus-mediated gene transfer of the VLDL receptor.
    van Dijk KW, van Vlijmen BJ, van der Zee A, van't Hof B, van der Boom H, Kobayashi K, Chan L, Havekes LM, Hofker MH.
    Arterioscler Thromb Vasc Biol; 1998 Jan 26; 18(1):7-12. PubMed ID: 9445249
    [Abstract] [Full Text] [Related]

  • 8. The p.Leu167del Mutation in APOE Gene Causes Autosomal Dominant Hypercholesterolemia by Down-regulation of LDL Receptor Expression in Hepatocytes.
    Cenarro A, Etxebarria A, de Castro-Orós I, Stef M, Bea AM, Palacios L, Mateo-Gallego R, Benito-Vicente A, Ostolaza H, Tejedor T, Martín C, Civeira F.
    J Clin Endocrinol Metab; 2016 May 26; 101(5):2113-21. PubMed ID: 27014949
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Hyperlipidemia in APOE2 transgenic mice is ameliorated by a truncated apoE variant lacking the C-terminal domain.
    Gerritsen G, Kypreos KE, van der Zee A, Teusink B, Zannis VI, Havekes LM, van Dijk KW.
    J Lipid Res; 2003 Feb 26; 44(2):408-14. PubMed ID: 12576523
    [Abstract] [Full Text] [Related]

  • 11. Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy.
    Hoffmann MM, Scharnagl H, Panagiotou E, Banghard WT, Wieland H, März W.
    J Am Soc Nephrol; 2001 Mar 26; 12(3):524-530. PubMed ID: 11181800
    [Abstract] [Full Text] [Related]

  • 12. Plasma ApoE4 Levels Are Lower than ApoE2 and ApoE3 Levels, and Not Associated with Plasma Aβ40/42 Ratio as a Biomarker of Amyloid-β Amyloidosis in Alzheimer's Disease.
    Nakamura T, Kawarabayashi T, Ueda T, Shimomura S, Hoshino M, Itoh K, Ihara K, Nakaji S, Takatama M, Ikeda Y, Shoji M.
    J Alzheimers Dis; 2023 Mar 26; 93(1):333-348. PubMed ID: 36970894
    [Abstract] [Full Text] [Related]

  • 13. Plasma lipoproteins in familial dysbetalipoproteinemia associated with apolipoproteins E2(Arg158-->Cys), E3-Leiden, and E2(Lys146-->Gln), and effects of treatment with simvastatin.
    Zhao SP, Smelt AH, Van den Maagdenberg AM, Van Tol A, Vroom TF, Gevers Leuven JA, Frants RR, Havekes LM, Van der Laarse A, Van 't Hooft FM.
    Arterioscler Thromb; 1994 Nov 26; 14(11):1705-16. PubMed ID: 7947593
    [Abstract] [Full Text] [Related]

  • 14. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia.
    Ji ZS, Fazio S, Mahley RW.
    J Biol Chem; 1994 May 06; 269(18):13421-8. PubMed ID: 8175773
    [Abstract] [Full Text] [Related]

  • 15. The role of apolipoprotein E genetic variants in lipoprotein disorders.
    Rall SC, Mahley RW.
    J Intern Med; 1992 Jun 06; 231(6):653-9. PubMed ID: 1619388
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The functional characteristics of a human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia.
    Horie Y, Fazio S, Westerlund JR, Weisgraber KH, Rall SC.
    J Biol Chem; 1992 Jan 25; 267(3):1962-8. PubMed ID: 1730728
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Genetic factors precipitating type III hyperlipoproteinemia in hypolipidemic transgenic mice expressing human apolipoprotein E2.
    Huang Y, Rall SC, Mahley RW.
    Arterioscler Thromb Vasc Biol; 1997 Nov 25; 17(11):2817-24. PubMed ID: 9409260
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.